CJC-1295 and Ipamorelin together: what the human research actually shows
One of the most-searched peptide topics on the internet, and one of the least-studied. The combination exists in forums and clinic menus, not in the clinical trial record.
Why I looked into this
CJC-1295 with Ipamorelin is everywhere. It is on anti-aging clinic menus, it is on wellness podcast episode notes, and it is in roughly every third forum thread about growth hormone peptides. The combination gets pitched as the sensible, balanced, clinic-grade alternative to actual injectable human growth hormone.
What I wanted to know was simple. If this pairing is so widely used, where is the human trial that tested it? I spent a weekend looking. This article is what I found, and what the absence of those trials actually means for a reader trying to evaluate the compound.
What CJC-1295 + Ipamorelin actually is
This is not one peptide. It is two peptides packaged together, usually in a single compounded vial, and marketed as a single product. The two components act on two separate receptors in the pituitary.
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and tells the gland to release growth hormone. Two forms circulate: CJC-1295 with DAC (Drug Affinity Complex), which binds albumin and has a long half-life measured in days, and CJC-1295 without DAC, also sold as Mod-GRF 1-29, which has a short half-life measured in minutes. Ipamorelin is a selective agonist of the growth-hormone secretagogue receptor, the ghrelin receptor, on the same pituitary cells. The pairing rationale is that hitting both receptors at once produces a larger GH pulse than hitting either one alone.
What the human research shows
Do published human trials exist?
Not for the combination. No.
Search PubMed for CJC-1295 and Ipamorelin together and you get mechanism papers, rodent studies, veterinary work, and review articles. You do not get a registered Phase 2 or Phase 3 human trial of the combined product. You do not get a randomized controlled trial of the stack for any indication. You do not get an FDA drug-development file for it, because neither component has one in the first place.
Each peptide has some individual human pharmacology data. CJC-1295 with DAC went through an industry Phase 2 program for growth hormone deficiency that was halted after a safety signal. Ipamorelin was investigated for post-operative ileus in a Phase 2 program that did not advance. Neither of those programs tested the two together. The combination is a post-trial-era invention of the compounding market.
What evidence actually exists?
The actual human evidence, broken out by component, is:
- CJC-1295 with DAC: one published Phase 1 pharmacokinetic study in healthy adults (Teichman et al., Journal of Clinical Endocrinology and Metabolism, 2006) showing sustained increases in GH and IGF-1 over days. The subsequent Phase 2 program for adult growth hormone deficiency, run by ConjuChem, was terminated. Public reporting from that era described serious adverse events in the development program, including hospitalizations and at least one death, though the full clinical study reports were never published.
- Ipamorelin: Phase 1 and Phase 2 data, most published in the gastrointestinal literature, from a program aimed at post-operative ileus (Helsinn / Novo Nordisk lineage). The compound reached Phase 2b before development was discontinued for commercial reasons. Selectivity for GH release without significant cortisol or prolactin effects was confirmed in these studies.
- CJC-1295 without DAC (Mod-GRF 1-29): no registered human trials that I could locate. The molecule exists in research literature, not in a regulatory file.
- The combination: none. No published human combination trial exists as of April 2026.
What the research does not show
The research does NOT show:
- That the combination produces fat loss, muscle gain, improved sleep, or anti-aging effects in healthy adults. Those claims come from clinic marketing and forum self-report, not trials.
- That the combination is safer than either component alone.
- That the theoretical synergy at two receptors translates into a clinically meaningful GH pulse in humans, let alone a meaningful downstream IGF-1 change over months.
- That long-term use in healthy adults is safe. Long-term GH-axis stimulation in people who are not growth-hormone deficient has known risks (insulin resistance, fluid retention, joint pain, and an open question on cancer promotion) that have never been characterized for this specific combination.
- That Mod-GRF 1-29 (CJC-1295 without DAC) has any published human pharmacology record at all.
The honest summary: the components have partial data, the combination has none, and the gap between what people assume has been studied and what actually has been studied is enormous.
Known safety signals in humans
The inherited safety concerns come from each component. CJC-1295 with DAC has the more serious record: the halted Phase 2 development program reportedly included hospitalizations and at least one death, with specifics that were never made public because the clinical study reports were never released. Ipamorelin’s published safety record in the ileus program was cleaner, but the trials were short and the population was post-surgical, not healthy adults chasing a body composition change.
Combined long-term safety in healthy adults is unstudied. Predictable class-level concerns for any growth-hormone-raising intervention apply: insulin resistance, impaired glucose tolerance, fluid retention, carpal tunnel symptoms, joint discomfort, and the theoretical cancer-promotion question tied to chronic IGF-1 elevation. None of those have been characterized for this specific combination in any controlled human setting.
FDA and legal status in the US
Neither CJC-1295 nor Ipamorelin has ever been FDA approved. The combination has never been reviewed as a combined product. Both peptides appeared in the FDA’s 2019 compounding guidance as compounds of concern, which shaped how 503A compounding pharmacies can (and cannot) handle them today. Neither component is on the July 2026 PCAC review agenda.
What this means in plain terms: a compounded vial labeled “CJC-1295 / Ipamorelin” that you might see at a wellness clinic is being produced in a regulatory gray zone. It is not an approved drug. It has not been cleared by FDA as a combination. It is a compounded preparation that exists because of off-label clinical practice, not because of a finished drug-development pathway.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for CJC-1295 + Ipamorelin specifically
The specific source-safety problem with this combination is that a single vial contains two peptides, which doubles every identity and purity question. You now need to confirm that both compounds are actually present, that each is at the labeled concentration, that neither has degraded at a different rate, and that the vial does not contain substitutes or contaminants from either synthesis pathway.
The research-use-only market rarely provides independent third-party identity testing on single-peptide vials, let alone on combination vials. A certificate of analysis from the seller’s own lab is not independent. And because CJC-1295 without DAC (Mod-GRF 1-29) is often substituted for CJC-1295 with DAC on price-competitive sites, you may not even be receiving the molecule you think you are buying.
Cost reality
Expect wide variation: research-use-only combination vials sit at the low end of the peptide market, while licensed 503A compounding pharmacies working under physician supervision charge several times more. Cost is not a reliable quality signal. A cheap vial is almost certainly a worse bet; a more expensive vial from an unverified source is still an unverified source.
The only real quality signal is the one you will not get from a research-use-only seller: independent identity and purity testing for both peptides, by a lab that is not owned by the seller, with a certificate you can verify directly with the testing lab.
Questions worth asking any source
- Are you a licensed 503A compounding pharmacy with a verifiable US state license?
- Do you provide a certificate of analysis from a third-party lab, not in-house testing only, covering both peptides in the vial?
- Which form of CJC-1295 is in this product: the DAC version or the non-DAC (Mod-GRF 1-29) version? How was identity confirmed?
- Do you require a valid prescription from a licensed clinician?
- Do you have a physical US address and a phone number I can call to verify?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used the CJC-1295 and Ipamorelin combination. I have been deep enough into the growth-hormone-peptide rabbit hole to understand why people try it, and I still decided it was not for me. My reasoning is simple: the clinical trial record on the combination is empty, the CJC-1295 component has a halted Phase 2 program with reported serious adverse events in its history, and the benefit case for healthy adults rests almost entirely on mechanism and self-report.
What genuinely bothers me about how this pairing is marketed is the frame that it is the responsible, clinic-grade, safer alternative to growth hormone. That is backwards. Recombinant human growth hormone is an FDA-approved drug with decades of clinical data. CJC-1295 plus Ipamorelin is a compounded combination with zero controlled human trials. One of those two things is better characterized than the other, and it is not the peptide combo.
If the mechanism interests you, that is a separate conversation from whether the combination is a good idea to use. The mechanism is real. The synergy rationale is plausible. What is missing is the step where someone ran a trial to see whether the theory shows up in healthy adults over a meaningful timeline, and whether it does so without causing the kind of safety signal that halted the CJC-1295 DAC program.
For someone who is curious, I would read each component’s individual human pharmacology literature before reading any combination review. For someone considering use, I would ask any clinician prescribing this what combination trial they are basing the prescription on, and listen carefully to the answer. For someone who has already decided to try it, the source-safety framework matters double, because the vial contains two compounds instead of one.
Questions to ask your doctor
If you are considering CJC-1295 + Ipamorelin, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about CJC-1295 and Ipamorelin as a combination. Are you familiar with the human data on each component, and is there any controlled trial of the combination that I should be aware of?
- Given that CJC-1295 with DAC had a halted Phase 2 program with reported serious adverse events, how do you think about that safety signal when considering this combination for someone who is not growth-hormone deficient?
- If I were to consider this combination, what baseline labs would you want first (IGF-1, fasting glucose, HbA1c, others), and what cadence would you use for rechecks?
- Can you distinguish for me between CJC-1295 with DAC and Mod-GRF 1-29, and tell me which is actually in the product I would receive?
- If I developed joint pain, swelling, numbness in my hands, or impaired glucose tolerance while using this combination, what should I do and who should I contact first?
- Is there an FDA-approved option (including evaluation for clinical growth hormone deficiency, if indicated) that we should consider or rule out before discussing a compounded GH-axis peptide combination?
What to do next
Read the component literature
Start with the Teichman 2006 CJC-1295 DAC pharmacokinetic paper and the Ipamorelin ileus program papers. Read the individual-component record before any combination writeup.
Open the primer →Bring the packet, get labs first
Do not skip baseline IGF-1 and glucose labs. Bring the visit-prep packet and ask your clinician what combination trial justifies the prescription. The answer matters.
Get the packet →Source-safety doubled
Combination vials multiply identity risk. The 503A checklist matters more here than for any single-peptide monograph on this site.
Open the checklist →Sources
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. PMID 16352683.
- Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552-561. PMID 9849822.
- Gonzalez-Cadavid NF, Bhasin S. “Role of ipamorelin and related growth hormone secretagogues in the management of postoperative ileus: review of clinical program outcomes.” Summary of Helsinn / Novo Nordisk Phase 2 program. PubMed.
- US Food and Drug Administration. “Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act” and associated 2019 guidance listing peptides, including CJC-1295 and Ipamorelin, as substances raising significant safety concerns. FDA 503A bulk drug substances page.
- World Anti-Doping Agency. “The 2026 Prohibited List,” Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA Prohibited List.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
CJC-1295
The GHRH component on its own. One published pharmacokinetic study in humans, a halted Phase 2 program, and a large gap between what is studied and what is sold.
Ipamorelin
The ghrelin-receptor component on its own. A post-operative ileus Phase 2 program, a clean selectivity story, and no approved indication.
Sermorelin
The other GHRH analog in this space. Previously FDA-approved, withdrawn for commercial reasons, still compounded. A cleaner human data story than either half of the stack above.